

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
16 October 2003 (16.10.2003)

PCT

(10) International Publication Number  
**WO 03/084559 A1**(51) International Patent Classification<sup>7</sup>: **A61K 35/78**

(21) International Application Number: PCT/US03/10200

(22) International Filing Date: 3 April 2003 (03.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/369,324 3 April 2002 (03.04.2002) US(71) Applicant (for all designated States except US): **ARCTOS  
PHARMACEUTICALS, INCORPORATED** [US/US];  
1531 Oxford Drive, Anchorage, AK 99503 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **MCKENZIE, Mau-  
reen, A.** [US/US]; P.O. Box 18, Girdwood, AK 99587  
(US).(74) Agents: **NATH, Gary, M.** et al.; Nath & Associates  
PLLC, Sixth Floor, 1030 15th Street, N.W., Washington,  
DC 20005 (US).(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: **VACCINIUM SPECIES COMPOSITIONS WITH NOVEL BENEFICIAL PROPERTIES**

(57) **Abstract:** This invention relates to novel compositions comprising as an active ingredient one or more berries, leaves, roots, and/or root barks obtained from one or more plant species of the genus *Vaccinium*, wherein said plant(s) is/are grown under the following conditions: a. Subject to one or more uninterrupted photoperiod(s) of at least about 18 hours to 24 hours per day for about 60 days during flowering and fruit setting; and; b. Subject to one or more uninterrupted photoperiod(s) of at least about 15 hours per day for about 30 days during fruit ripening and maturity. More particularly, said plant(s) is/are optionally grown at least 7 days past maturity. Further, the compositions of the inventive subject matter optionally may include an additional element comprising an oil from *Oncorhynchus* species. Further, said compositions may be employed to treat a variety of diseases, disorders, and conditions, as described herein.

**VACCINIUM SPECIES COMPOSITIONS WITH NOVEL**  
**BENEFICIAL PROPERTIES**

This application claims the benefit of U.S. Provisional Patent Application No. 60/369,324, filed April 3, 2002, the contents of which is hereby incorporated by reference in its entirety.

**BACKGROUND OF THE INVENTION**

**1. Field of Invention**

10 This invention relates to novel compositions comprising as an active ingredient one or more berries, leaves, roots, and/or root barks obtained from one or more plant species of the genus *Vaccinium*, wherein said plant(s) is/are grown under the following conditions:

- 15 a. Subject to one or more uninterrupted photoperiod(s) of at least about 18 hours to 24 hours per day for about 60 days during flowering and fruit setting; and
- 20 b. Subject to one or more uninterrupted photoperiod(s) of at least about 15 hours per day for about 30 days during fruit ripening and maturity.

More particularly, said plant(s) is/are optionally grown at least 7 days past maturity. Further, the compositions of the inventive subject matter optionally may include an additional element comprising an oil from *Oncorhynchus* species. Further, said compositions may be employed to treat a variety of diseases, disorders, and conditions, as described herein.

**2. Background**

There are approximately 90, of approximately 400 species of *Vaccinium*, that are distributed widely across the Northern Mediterranean, Southern Europe, Central Europe, Northern Europe, North Asia, South Asia, Central Asia, and East Asia. This includes approximately 50 species

native to North America. Bilberry, blueberry, huckleberry, cranberry, and lingonberry fruits of the *Vaccinium* genus are a rich source of anthocyanosides, a group of red to blue plant pigments, which exist as condensed products, glycosides, of anthocyanins, known as anthocyanidins, combined usually with sugar(s) such as glucose, arabinose, and galactose.

Oxidative stress is an imbalance between oxidants and antioxidants in favor of the former, resulting in oxidative damage to molecules such as DNA, lipids, and proteins. In humans, free radicals are produced by metabolic processes, cigarette smoke, photochemical smog, pesticides, and drugs, among others. The consumption of antioxidant-rich fruits and vegetables has been associated with lower incidence and lower mortality rates of all common cancers. Further, epidemiological data, human clinical trials, and animal studies suggest that dietary antioxidants and diets rich in vegetables and fruits decrease cardiovascular disease and increase longevity. A number of studies have shown that mortality from coronary heart disease is inversely correlated with intake of substances found in certain fruits. Experts have suggested that a recommended minimum daily requirement for dietary antioxidants be established.

Some of the components present within *Vaccinium* are expected to have multiple health benefits. *V. myrtillus* scores highest among 50 fruits and vegetables in its ability to defuse damaging oxygen free radicals in the ORAC assay. ORAC analysis of commercial blueberry varieties and less common wild species from the United States and Canada has shown that consumption of one-half cup, 72.5 g, of blueberries per day increases ORAC intake by 1-3.2 mmol, depending upon the blueberry variety and maturity, making a small contribution to a healthy diet for normal individuals.

The antioxidant capacity of blueberries varies considerably. European bilberry has been reported to have

the highest anthocyanin content of *Vaccinium* species, 300-698 mg anthocyanin/ 100 g. The total antioxidant capacity, measured as ORAC, ranges from a low of 13.9 to 44.6 mmol TE/g fresh berries in the acetonitrile extracts of the  
5 different cultivars of blueberries.

Applicant has surprisingly found that, on a fresh weight basis, Alaskan *Vaccinium* species have the highest antioxidant capacity of all *Vaccinium* berries tested to date, including European bilberry. Further, the Alaskan  
10 *Vaccinium* preparation provided in the inventive subject matter, ORAC values observed are, across the board with various radicals, unprecedented and unexpected. Applicant has found that, under the growing conditions specified in detail below, *Vaccinium* species produce an unexpectedly  
15 high level of the metabolites producing the observed ORAC, anthocyanin, proanthocyanidin, and phenolic content.

Unlike other berries, the extremely high content of anthocyanins and polyphenols in high latitude berries, exemplified by Alaskan berries allows unique formulation as  
20 a dehydrated whole food, compared to others that require extraction to concentrate beneficial molecules. The berries of the inventive subject matter provide a meaningful dose after only a mild refractance window drying step, without any additional processing or extraction. In the inventive  
25 compositions, all of the substances are retained in essentially natural ratios. As a base for product formulation, dehydrated *Vaccinium* rich in hydrophilic antioxidants is enhanced with oils from, for example, *Oncorhynchus* (salmon) species, that naturally contain  
30 lipophilic Vitamin E and other substances, including carotenoids, such as astaxanthin, and omega-3 and omega-6 fatty acids.

These factors are expected to make high latitude berries, exemplified by Alaskan berries a previously  
35 unrecognized, preferred substance for an antioxidant nutraceutical supplement. A product formulated by the



inventive methods is expected to retain its preferred whole food composition, and receive less restrictive regulatory status.

5

**SUMMARY OF THE INVENTION**

The present invention relates to a composition comprising:

i. one or more berries, leaves, roots, and/or root barks obtained from one or more plant species of the genus  
10 *Vaccinium*, wherein said plant(s) is/are grown under the following conditions:

(a) Subject to one or more uninterrupted photoperiod(s) of at least about 18 hours to 24 hours per day for about 60 days during flowering  
15 and fruit setting; and

(b) Subject to one or more uninterrupted photoperiod(s) of at least about 15 hours per day for about 30 days during fruit ripening and maturity.

20 The present invention further relates to a method for treating a disorder in an animal, which comprises administering to said animal an effective amount of a composition comprising one or more berries, leaves, roots, and/or root barks obtained from one or more plant species  
25 of the genus *Vaccinium*,

wherein said plant(s) is/are grown under the following conditions:

i. Subject to one or more uninterrupted photoperiod(s) of at least about 18 hours to 24 hours per day for about 60 days during flowering  
30 and fruit setting; and

ii. Subject to one or more uninterrupted photoperiod(s) of at least about 15 hours per day for about 30 days during fruit ripening and  
35 maturity;

and wherein said disorder is selected from the group

consisting of diabetes mellitus, inflammatory disorders, ulcers, viral diseases or disorders, microbial diseases or disorders, interstitial fluid formation, capillary resistance and permeability, decreased platelet  
5 aggregation, eyestrain, diabetic retinopathy, macular degeneration, cataracts, glaucoma, cancer, obesity, atherosclerosis, and cardiovascular disease; for improving visual function by promoting dark adaptation, enhancing the activity of metabolic enzymes in the retina, improving  
10 retinal regeneration, improving visual acuity, night vision, and contrast sensitivity; and for promoting wound-healing, normal formation of connective tissue, and strengthening of capillaries.

The present invention further relates to a product  
15 produced by the process of:

i. Growing a plant of a species of the genus *Vaccinium* under the following conditions:

(a) Subject to one or more uninterrupted photoperiod(s) of at least about 18 hours to 24  
20 hours per day for about 60 days during flowering and fruit setting,

(b) Subject to one or more uninterrupted photoperiod(s) of at least about 15 hours per day for about 30 days during fruit ripening and  
25 maturity, and

(c) Grown at least about 7 days past peak fruit ripeness;

ii. Harvesting berries, leaves, roots, and/or root barks from said plant; and

30 iii. Drying said berries, leaves, roots, and/or root barks from said plant.

The inventive subject matters also relates to a composition comprising berries obtained from one or more plant species of the genus *Vaccinium*, wherein said plant(s)  
35 is/are processed according to the following steps:

(a) Exposed to one or more uninterrupted

photoperiod(s) of at least about 18 hours to 24 hours per day for about 60 days during flowering and fruit setting;

5 (b) Exposed to one or more uninterrupted photoperiod(s) of at least about 15 hours per day for about 30 days during fruit ripening and maturity;

(c) Grown at least about 7 days past peak fruit ripeness;

10 (d) Dried; and

(e) Formulated into a therapeutic or nutritional composition having about 0.1 mg to about 100 mg per kilogram body weight of active ingredients.

15 **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 is a chart which depicts Hydrophilic ORAC ranking of fruits.

20 Figure 2 is a chart which depicts ORAC values of the berries of the inventive subject matter for peroxy radical in hydrophilic and hydrophobic conditions, as well as for hydroxyl and peroxynitrite radicals.

Figure 3 is a graph which depicts separation of 10 common anthocyanins using RP-HPLC with UV detection for Alaskan berries.

25 Figure 4 is a graph which depicts anthocyanin profiles of a cultivated blueberry standard.

Figure 5 is a graph which depicts an HPLC chromatogram at 280 nm of the total phenolics profile of wild Alaskan Blueberries.

30 Figure 6 is a graph and chart which depict an HPLC chromatogram at 280 nm of the total phenolics profile of a cultivated blueberry standard, and the characterization of phenolic compounds using RP-HPLC with UV detection.

35 Figure 7 is a chart which depicts the antioxidant fingerprint obtained by multi-channel ECD Detector for wild Alaskan Blueberries.

Figure 8 is a chart which depicts antioxidant fingerprint obtained by the ESA 8-channel electron chemical detector for a cultivated blueberry standard.

Figure 9 is a chart which depicts the rank of  
5 antioxidant activity against hydroxyl radicals of fruits.

Figure 10 is a graph and chart which depict the proanthocyanin profile of Alaskan Blueberries and the proanthocyanidin content of Alaskan Blueberries, blueberry, cocoa, and cranberry.

10 Figure 11 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry leaves in ethyl acetate.

Figure 12 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of  
15 wild Alaskan Blueberry stems in ethyl acetate.

Figure 13 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry stalks in ethyl acetate.

Figure 14 is a graph which depicts an HPLC  
20 chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry root in ethyl acetate.

Figure 15 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry leaves in hexane.

25 Figure 16 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry leaves in dichloromethane.

Figure 17 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of  
30 wild Alaskan Blueberry leaves in dichloromethane.

Figure 18 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry leaves in ethyl acetate.

Figure 19 is a graph which depicts an HPLC  
35 chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry leaves in acetonitrile.

Figure 20 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry leaves in acetonitrile.

Figure 21 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry leaves in ethanol.

Figure 22 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry leaves in ethanol.

Figure 23 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry stalks in hexane.

Figure 24 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry stalks in dichloromethane.

Figure 25 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry stalks in dichloromethane.

Figure 26 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry stalks in ethyl acetate.

Figure 27 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry stalks in acetonitrile.

Figure 28 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry stalks in acetonitrile.

Figure 29 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry stalks in ethanol.

Figure 30 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry stalks in ethanol.

Figure 31 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry stems in hexane.

Figure 32 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry stems in dichloromethane.

Figure 33 is a graph which depicts an HPLC  
5 chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry stems in dichloromethane.

Figure 34 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry stems in ethyl acetate.

10 Figure 35 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry stems in acetonitrile.

Figure 36 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of  
15 wild Alaskan Blueberry stems in acetonitrile.

Figure 37 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry stems in ethanol.

Figure 38 is a graph which depicts an HPLC  
20 chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry stems in ethanol.

Figure 39 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry root in hexane.

25 Figure 40 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry root in dichloromethane.

Figure 41 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of  
30 wild Alaskan Blueberry root in dichloromethane.

Figure 42 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry root in ethyl acetate.

Figure 43 is a graph which depicts an HPLC  
35 chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry root in acetonitrile.

Figure 44 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry root in acetonitrile.

Figure 45 is a graph which depicts an HPLC  
5 chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry root in ethanol.

Figure 46 is a graph which depicts an HPLC chromatogram at 200 nm of the total phenolics profile of wild Alaskan Blueberry root in ethanol.

10 Figure 47A is a graph and chart which depict an HPLC chromatogram at 280 nm of the total phenolics profile of wild Alaskan Blueberry root in ethyl acetate, and the characterization of phenolic compounds using RP-HPLC with UV detection.

15 Figure 47B is a graph which depicts an ultraviolet scan of peak 7 found in Figure 47A

**DETAILED DESCRIPTION OF THE INVENTION****Definitions**

"ORAC" refers to the Oxygen Radical Absorbing Capacity developed by the United States Department of Agriculture.

5 "TE" refers to Trolox Equivalents used in ORAC assays; Trolox is a water-soluble analog of Vitamin E.

"Anti-oxidant" refers to a chemical substance with the ability to scavenge oxygen "free radicals."

10 "Free Radical" refers to a compound having an unpaired electron, particularly an unpaired electron associated with an oxygen atom of the compound.

"Maturity" refers to the growth phase of *Vaccinium* species plants following fruit set, when organoleptic properties of fruit, for example, pigment, taste, and  
15 texture, are fully-developed and acceptable for human consumption as food.

"Peak ripeness" refers to the time in *Vaccinium* plant maturity when fruits have full, uniform coloring; are flavorful; and have begun to soften.

20 "High latitude" refers to a latitude which is at least about 55 degrees north or south of the equator of the Earth.

"Photoperiod" refers to a time of extended or continuous exposure to sunlight and, in particular, UV-B  
25 radiation.

"Freeze/thaw cycle" or "freeze cycle" refers to a period when berries are converted from fresh to frozen or from thawed to frozen again, either pre- or post-harvest.

30 "Phytochemicals" refers to naturally occurring chemical substances in plants, including phenylpropanoid pathway compounds, having biological activities.

"Refractance window drying" refers to a publicly disclosed drying method that uses a heat transfer process and specific properties of water to gently remove moisture  
35 while maintaining the maximum integrity of natural material(s) in the substance being dried.



"Milk derivative" refers to a substance derived from the milk of mammals, including, for example, cream, yogurt, cottage cheese, sour cream, soft and hard cheeses, butter and other dairy spreads, and the like. This term further  
5 refers to non-dairy substitutes for their dairy equivalents, such as margarine.

"Effecting" refers to the process of producing an effect on biological activity, function, health, or condition of an organism in which such biological activity,  
10 function, health, or condition is maintained, enhanced, diminished, or treated in a manner which is consistent with the general health and well-being of the organism.

"Enhancing" the biological activity, function, health, or condition of an organism refers to the process of  
15 augmenting, fortifying, strengthening, or improving.

"Physiologically acceptable carrier", refers, but is not limited to, pharmaceutically acceptable tablets, capsules, powders, solutions, dispersions, or liquids for oral administration. The subject compositions may be  
20 compounded with other physiologically acceptable materials which can be ingested, including, but not limited to, foods such as food bars, beverages, powders, cereals, cooked foods, food additives, and candies. Another ingestible form is a dietary supplement, such as a snack or wellness  
25 dietary supplement, which may be in oral formulation(s) such as tablets, capsules, powders, bars, solutions, dispersions, or liquids.

30 **VACCINIUM SPECIES COMPOSITIONS AND**  
**METHODS FOR USING SAME**

**Compositions of the Inventive Subject Matter**

The present invention relates to a composition comprising:

- 35 i. one or more berries, leaves, roots, and/or root barks obtained from one or more plant species of the genus *Vaccinium*, wherein said plant(s) is/are grown under the

following conditions:

(a) Subject to one or more uninterrupted photoperiod(s) of at least about 18 hours to 24 hours per day for about 60 days during flowering and fruit setting; and

(b) Subject to one or more uninterrupted photoperiod(s) of at least about 15 hours per day for about 30 days during fruit ripening and maturity.

In another aspect of the inventive subject matter, said plant(s) is/are grown for at least about 7 days past peak fruit ripeness. Additional growth past peak ripeness permits additional production and concentration of beneficial substances in the plant(s).

The growing conditions of the inventive subject matter comprise growth of plant(s) at a latitude greater than 55 degrees north or south of the equator of the Earth. More preferably, in order to obtain the benefits described herein, the growing conditions comprise growth of said plant(s) at a latitude greater than 66 degrees north or south of the equator of the Earth.

In a preferred embodiment, growth conditions comprise the additional step of exposing said plant(s) to one or more freeze cycle(s) during growth and/or post-harvest. In this aspect of the inventive subject matter, processing the berries with a freezing step is expected to induce phenylpropanoid pathway enzymes and either stabilize or improve the ORAC values. Therefore, these factors are expected to make Plant(s) berries a previously unrecognized, preferred substance for an antioxidant nutraceutical supplement. A product formulated by this method would retain its preferred whole food composition and more lenient regulatory status.

In an alternate aspect of the inventive subject matter, the composition is produced by the additional step of drying said berries, leaves, roots, and/or root barks.

More preferably, said drying step is a refractance window drying process.

A particular advantage of the inventive subject matter is that it does not require an independent processing, extraction, or concentration step, as is now required in the prior art to produce a physiologically significant quantity of beneficial substances. Thus, in a composition of the inventive subject matter, said dried berries, leaves, roots, and/or root barks do not require an additional processing or extraction step.

A composition of the inventive subject matter is produced from one or more plant species of the genus *Vaccinium*, selected from the group consisting of *V. alaskensis*, *V. axillare*, *V. caespitosum*, *V. caespitosum* var. *paludicola*, *V. membranaceum*, *V. parvifolium*, *V. ovalifolium*, *V. oxycoccus*, *V. shikokianum*, *V. uliginosum* subsp. *alpinum*, *V. uliginosum* var. *salicinum*, *V. uliginosum* subsp. *microphyllum*, *V. vitis-idaea* subsp. *minus*, *V. vitis-idaea* subsp. *vitis-idaea*.

A composition of the inventive subject matter most preferably comprises the berries of said plant(s).

Further, as will be apparent to one of ordinary skill in the art, the growth conditions and processing steps of the inventive subject matter may readily be combined in various combinations, as described in the following aspects of the inventive subject matter:

In another aspect of the inventive subject matter, a nutraceutical would be prepared from berries having undergone at least one freeze-thaw cycle prior to harvest, cleaned of debris, pureed, and dehydrated by refractance window drying. The dried granular material is then milled into a fine powder for use in various dosage forms.

In another preferred embodiment, a nutraceutical would be prepared from berries not having undergone at least one freeze-thaw cycle prior to harvest, but would be cleaned of debris and frozen and thawed post-harvest for at least one

cycle. Upon thaw, frozen berries would be pureed, and dehydrated by refractance window drying. The dried granular material is then milled into a fine powder for use in various dosage forms.

5        In another aspect of the inventive subject matter, a nutraceutical would be prepared from berries having undergone at least one freeze-thaw cycle prior to harvest, cleaned of debris and frozen and thawed at least once. Upon thaw, frozen berries would be pureed, and dehydrated by  
10 refractance window drying. The dried granular material is then milled into a fine powder for use in various dosage forms.

      In another aspect of the inventive subject matter, phytopharmaceutical substances would be made from berries  
15 having undergone at least one freeze-thaw cycle prior to harvest or post-harvest and extracted with an appropriate solvent to concentrate specific types of substances from forms processed further as described above.

      In another aspect of the inventive subject matter,  
20 phytopharmaceutical substances would be made from berries having undergone at least one freeze-thaw cycle prior to harvest or post-harvest and extracted with an appropriate solvent to concentrate specific types of substances from forms not processed further as described above.

25        In another aspect of the inventive subject matter, phytopharmaceutical substances would be made from berries not having undergone at least one freeze-thaw cycle prior to harvest or fresh, post-harvest and extracted with an appropriate solvent to concentrate specific types of  
30 substances from forms further processed as described above.

      In another aspect of the inventive subject matter, phytopharmaceutical substances would be made from berries not having undergone at least one freeze-thaw cycle prior to harvest or fresh, post-harvest and extracted with an  
35 appropriate solvent to concentrate specific types of substances from forms not processed as described above.

In another aspect of the inventive subject matter, pharmaceutical substances would be made from fresh berries or berries having undergone at least one freeze-thaw cycle prior to harvest or post-harvest and extracted with an appropriate solvent to concentrate specific types of substances from processed or unprocessed forms as described above.

In another aspect of the inventive subject matter, aerial parts, for example leaves, stem, and stem bark, may be an additional component of nutraceuticals from processed or unprocessed forms of berries as described above.

In another aspect of the inventive subject matter, roots and root bark may be an additional component of the types of nutraceuticals from processed or unprocessed forms of berries as described above.

In another aspect of the inventive subject matter, phytopharmaceuticals would be made from aerial parts, flowers, leaves, stem and stem bark, or root and root bark extracted with an appropriate solvent to concentrate specific types of substances from *Vaccinium* species with characteristics as described above.

In another aspect of the inventive subject matter, pharmaceuticals would be made from aerial parts, flowers, leaves, stem and stem bark, or root and root bark extracted with an appropriate solvent to concentrate specific types of substances from *Vaccinium* species with characteristics as described above.

Plants of the Genus *Vaccinium*. There are approximately 90, of approximately 400 species of *Vaccinium*, that are distributed widely across the Northern Mediterranean, Southern Europe, Central Europe, Northern Europe, North Asia, South Asia, Central Asia, and East Asia. This includes approximately 50 species native to North America. Essentially wherever humans migrated, to bogs, damp forests, whether temperate or subtropical, broadleaf or conifer, there were blueberries of varying

degrees of edibility, productivity, and population density. *Vaccinium* is a genus with a very long association with the part of the human race that radiated out of Africa and across Beringia. The berries of the inventive subject  
 5 matter are selected from high latitude species of the genus *Vaccinium* found in Alaska and neighboring territories.

The *Vaccinium* genus is taxonomically complex. Hybridization and polyploidy make delineation of species notoriously difficult. For example, dwarf bilberry, *V.*  
 10 *myrtillus*, is believed to have received genetic material from globe huckleberry, *V. globulare*, blue huckleberry, *V. membranaceum*, and/or dwarf huckleberry, *V. caespitosum*. Conversely, some taxonomists believe that the blue huckleberry may be a derivative of globe huckleberry and  
 15 dwarf bilberry. Naturally occurring dwarf bilberry-lingonberry, *V. vitis-idaea*, hybrids have been reported in parts of northern Europe. Numerous intermediate forms have been observed, although fruit set is apparently rare in these hybrid populations. *V. X intermedium* is a natural  
 20 hybrid resulting from a dwarf bilberry-lingonberry cross.

Subspecies and varieties of some of the species occurring in Alaska and neighboring territories have northern circumpolar ranges, and include *V. oxycoccus*, *V. uliginosum*, and *V. vitis-idaea*. Interestingly, the most  
 25 common *Vaccinium* species, *V. myrtillus*, is not found in Alaska. *Vaccinium* species occurring in Alaska and likely at the border of neighboring territories that are not typical species of commerce are described in Table 1.

30	Species Name	Location
	<i>V. alaskensis</i>	SC, SE
	<i>V. axillare</i>	Japan, (A) *
	<i>V. caespitosum</i>	SC, SE, Canada
	<i>V. caespitosum</i> var. <i>paludicola</i>	SC*

	<i>V. membranaceum</i>	Canada, (SE)*
	<i>V. parvifolium</i>	SE, Canada
	<i>V. ovalifolium</i>	A, SC, SE, SW
	<i>V. oxycoccus</i>	Ubiquitous
5	<i>V. shikokianum</i>	Japan, (A)*
	<i>V. uliginosum subsp. alpinum</i>	Throughout AK
	<i>V. uliginosum var. salicinum</i>	Scattered
	<i>V. uliginosum subsp. microphyllum</i>	A, FN, SC
	<i>V. vitis-idaea subsp. minus</i>	Throughout AK
10	<i>V. vitis-idaea subsp. vitis-idaea</i>	Kamchatka, (A)*

---

Table 1. *Vaccinium* species of Alaska and neighboring territories. A = Aleutians; (A)\* = predicted in the western Aleutians; AK = Alaska; FN = Far North Alaska; SC = Southcentral Alaska; SC\* = Southcentral, specifically Prince William Sound; SE = Southeast Alaska; (SE)\* = predicted in Southeast Alaska; SW = Southwest Alaska.

The Phenylpropanoid Pathway. Plants produce a distinct group of secondary metabolites collectively named flavonoids. The pathway that leads to flavonoid synthesis is a branch of the general phenylpropanoid pathway that exists in all higher plants. Genes encoding enzymes of this pathway are developmentally and tissue-specifically regulated and are expected to be induced by environmental stresses such as nutrient deficiency, drought, prolonged cold, exposure to intense UV light, and pathogen attack. The flavonoids, which are the best defined group of polyphenols in the human diet, themselves comprise a large and complex group, all of which contain a three-ring structure with two aromatic centers and a central oxygenated heterocycle.

Important metabolites of the phenylpropanoid pathway are isoflavones such as quercetin, myrtillin, daidzein, and genistein; flavanols, such as catechin and epicatechin; pterocarpanes such as medicarpin and glyceollins;

anthocyanins and anthocyanosides such as cyanidin, delphinidin, malvidin, petunidin, and peonidin; proanthocyanidins or tannins, and lignin. The isoflavonoids are essential for different types of plant-microbe  
5 interactions, and are also important chemoattractants and signal molecules for symbiotic bacteria. Different isoflavonoids are also either precursors to, or are themselves the major phytoalexins in plants, which play key roles in non-specific plant defense against bacterial and  
10 fungal pathogens. The activation of isoflavonoid synthesis during the disease resistance response is important for providing these many defense compounds. As a major part of their role as defense compounds against stress and disease, most of the phenylpropanoid pathway metabolites protect  
15 plants against oxidative stress.

Antioxidants. Oxidative stress is defined as an imbalance between oxidants and antioxidants in favor of the former, resulting in oxidative damage to molecules such as DNA, lipids and proteins. After life-long free-radical  
20 insult on an organ which already shows increased vulnerability to OS, functional deficits are observed. Since its introduction almost 50 years ago, the free radical hypothesis of aging has become popular to explain age-related changes that result from an increasing  
25 inability to cope with oxidative stress that occurs throughout the life-span from aerobic metabolism and is associated with increasing sensitivity to the effects of oxidative stressors.

"Free Radicals" are characterized by an unpaired  
30 electron associated with an oxygen atom of a compound. They are very unstable and quickly react with other compounds. In biological systems, common radicals produced include the peroxy radical, which is the most common radical in biological systems; the hydroxyl radical; the superoxide  
35 radical, which is produced by phagocytic cells and is beneficial in inactivating viruses and bacteria; the nitric



oxide radical, which has some beneficial effects as a vasodilator and a neurotransmitter; the peroxynitrite anion, which is produced by the reaction of nitric oxide with superoxide; and hydrogen peroxide, which is not  
5 technically a free radical, but is formed from reactions of free radicals and can also cause damaging oxidative events in cells. In humans, free radicals are produced by metabolic processes, cigarette smoke, photochemical smog, pesticides, and drugs, among others.

10       Conversely, an antioxidant is any substance that, when present at low concentrations compared to those of an oxidizable substrate, significantly delays or prevents the oxidation of such substrate, by "absorbing" the unpaired electron. The normal antioxidant defense systems in  
15 biological organisms are both enzymatic and nonenzymatic. Although both are important in biological systems, foods furnish nonenzymatic antioxidants such as  $\alpha$ -tocopherol, ascorbic acid, glutathione, flavonoids,  $\beta$ -carotene, uric acid, and proteins such as albumin, ceruloplasmin,  
20 transferrin, and metallothionein.

      Researchers have analyzed ORAC of commercial blueberry varieties and less common species from the United States and Canada, and compared them to the closely related bilberry from Germany. Highbush blueberry, *V. corymbosum*,  
25 and lowbush blueberry, *V. angustifolium*, are the primary species of blueberries used by the food industry in the United States. In recent days, the USDA asserts that consumption of one-half cup, 72.5 g, of blueberries per day increases ORAC intake by 1-3.2 mmol, depending upon the  
30 blueberry variety and maturity, making a small but beneficial contribution to a healthy diet for normal individuals.

      The antioxidant capacity of blueberries varies considerably because of the wide range of reported  
35 anthocyanin concentrations. Bilyk and Sapers (1986) found

that four varieties of cultivated highbush blueberry had total anthocyanin concentrations that varied by about 15%. Highbush blueberries have been reported to have an anthocyanin content of 25-495 mg/100 g fresh weight. Gao and Mazza (1994) reported, using HPLC techniques to measure anthocyanins, that most highbush blueberry samples contained about 100 mg anthocyanins/100 g and lowbush blueberry cultivars contained 150-200 mg anthocyanins/ 100 g. Others report that lowbush blueberries, grown in Maine and Eastern Canada, have about 138 mg anthocyanins per 100 g. Rabbiteye blueberries, *V. ashei*, grown in the southern U.S., have an anthocyanin content in the range of 62 mg/100 g to 210-272 mg/100 g. In contrast, bilberry has been reported to have the highest anthocyanin content of 300-698 mg anthocyanin/ 100 g.

According to studies performed by Prior and colleagues, the total antioxidant capacity, measured as ORAC, ranged from a low of 13.9 to 44.6 mmol TE/g fresh berries in the acetonitrile extracts of the different cultivars of blueberries. The overall mean of all commercially available cultivars was 24.0+/-2.0. Certain highbush varieties and late harvest rabbiteye cultivars had ORAC values (i.e. 32.4, 37.1, 42.3, 37.8, and 34.3 TE/g, respectively) that approached the value observed for the bilberry (44.6 TE/g). It has been suggested that region does not affect the antioxidant score, based on analyses by the USDA Human Nutrition Research Center on Aging at Tufts University (Boston, MA) of berries from the northern highbush variety, Jersey, grown in Oregon, Michigan and New Jersey.

There appears, however, to be two clusters of ORAC values in the lowbush blueberries. The first included lowbush from Prince Edward Island and Nova Scotia, and Fundy lowbush blueberries which are relatively high in ORAC (mean: 41.8 TE/g), anthocyanins, and total phenolics. The second cluster included lowbush from Maine, and lowbush

blueberries from other locations which are lower in ORAC (mean: 27.5 TE/g). At this time, the source of this variation, whether genetics, location, maturity or other factors, is not clear. Anthocyanins in the lowbush  
5 blueberries are not as high as the bilberry relative to ORAC values as reflected in the ratio of anthocyanins to ORAC, 0.37 TE/g versus 0.57 TE/g. Further, the results of Prior et al. in general seem to be a little lower than some of the other reports; however, the particular anthocyanin  
10 compound used as a standard and its associated molar absorption coefficient can influence the absolute amounts calculated.

Maturity at harvest had a marked effect on ORAC, total anthocyanins and total phenolics of the berries, as  
15 demonstrated for the cultivars of rabbiteye blueberries. Berries harvested immediately after turning blue had lower ORAC and total anthocyanins than well-matured berries that were harvested 49 days later. ORAC and total anthocyanins increased 224% and 261% respectively, in one cultivar,  
20 while they increased in the other cultivar by 164% and 176% respectively, with increasing maturity. Total phenolics increased by 169% and 113% in these cultivars, with increased maturity.

Ascorbate concentrations (1.3-16.4 mg/100 g) showed a  
25 significant variability between cultivars and species, but are typically less than or equal to 10% of the total ORAC. Although most of the samples had an ascorbate concentration between 9-16 mg/100 g, no consistent pattern emerged relative to ORAC, anthocyanins or total phenolics. Using an  
30 ORAC value for ascorbate of 5.6 mmol TE/g, it was calculated that the antioxidant capacity contributed by ascorbate to the total antioxidant capacity, measured as ORAC, was 2.3% for the highbush and rabbiteye berries. Ascorbate in lowbush berries contributed only 1.5% while in  
35 the bilberry sample, the contribution of ascorbate to ORAC was only 0.2%. Thus, it is clear that ascorbate does not

make a major contribution to the antioxidant capacity of any of the blueberries sampled.

Advantages of the Inventive subject matter. On a fresh weight basis, Alaskan *Vaccinium* species have the highest antioxidant capacity of all *Vaccinium* berries tested to date, including European bilberry. For a comparison of the ORAC value of the berries of the inventive subject matter to others, see Figure 1. Expressed in a different way, on a mmol/g basis, for peroxy radical in hydrophilic and hydrophobic conditions, as well as for hydroxyl and peroxynitrite radicals, see Figure 2 and Figure 3?). This is unprecedented according to Wang and Jiao (2000), who found unique patterns of oxygen radical scavenging ability in different berry genera. Overall, fruit juice from different cultivars of 'Hull Thornless' blackberry, 'Earliglow' strawberry, 'Early Black' cranberry, 'Jewel' raspberry, and 'Elliot' blueberry had the highest antioxidant capacity against superoxide radicals, peroxy, hydroxyl radicals, and singlet oxygen. Blackberries had the highest antioxidant capacity inhibition of superoxide, peroxy, and hydroxyl radical. Strawberry was second best in the antioxidant capacity assay for these same free radicals. With regard to singlet oxygen scavenging activity, strawberry had the highest value, while blackberry was second. Cranberries had the lowest inhibition of peroxy activity. Meanwhile, blueberries had the lowest antioxidant capacity against hydroxyl and singlet oxygen, in direct contrast to the results of hydroxyl radical scavenging by Alaska *Vaccinium*. Further, in the Alaskan *Vaccinium* preparation, total anthocyanin concentration is 37.43 mg/g and total phenolic content is 69.63 mg/g on a dry weight basis. The value for bilberry, on a fresh weight basis, is cited in the literature as the highest, at 300-698 mg anthocyanin/100 g, depending upon the anthocyanin reference compound used for comparison, and 525 mg/100g total phenolics. Prior et al.,

utilizing cyanidin 3-glucoside as a standard, found the average bilberry anthocyanin concentration to be 299.5 mg/100 g fresh weight. Compared to the same standard, the anthocyanin concentration of Alaska *Vaccinium* is estimated  
5 to be 312-333 mg/100 g fresh weight, and the total phenolics are 580-619 mg/100 g fresh weight.

The ORAC values observed are, across the board with various radicals, and the correlation to anthocyanin, proanthocyanidin, and phenolic content are unprecedented  
10 and were not predicted. The bilberry has always dominated such comparisons and, based on those, regulatory agencies such as the German Commission E regard any other *Vaccinium* source as a possible adulterant to *V. myrtillus* preparations.

15 Although most researchers would argue that *Vaccinium* is selective about its growing conditions, and that these influence antioxidant concentrations in unknown ways, Applicant expected a link between growing conditions and antioxidant content of Alaskan *Vaccinium* berries. Without  
20 being bound by any particular theory of mechanism of action, Applicant believes that the metabolites producing the observed ORAC, anthocyanin, proanthocyanidin, and phenolic content are generated by one or more stress-related phenylpropanoid pathway(s). At the very high  
25 latitudes where berries grow in Alaska, the photoperiod is greater than 17.5 hours at 55 degrees north and is continuous at 66 degrees north for approximately 3 months. Applicant believes that UV-B is strongest at low latitudes and high altitudes, that the ultraviolet bombardment at  
30 such latitudes produces the surprising results found, and expects that lower latitude plants do not produce such results because of the presence of a significant daily dark period. At higher latitudes, the sun is always low in the sky so that it takes a longer path through the atmosphere  
35 and more of the UV-B is absorbed. As unexpectedly discovered by Applicant, high latitude plants, exemplified

by Alaskan plants, must synthesize a great deal of antioxidants to protect DNA, proteins, and lipids from free radical damage. Further, Applicant expects that the widely documented and publicized ozone-depletion at high latitudes makes exposure to UV-B even more intense than previously believed.

Applicant expects that the novel characteristics of high latitude berries, exemplified by Alaskan berries, results in part from the relatively low levels of annual precipitation in the Far North region of 4.8 inches, and in the Interior region of 10.8 inches, would enhance the phenylpropanoid pathway metabolites of the berries. In the Southcentral and Southeast regions, precipitation is 15.9 inches, and 54.38 inches, respectively, that are expected to actually enhance UV-B exposure due to prolonged cloud cover.

Further, Applicant expects that the novel characteristics of high latitude berries, exemplified by Alaskan berries, results in part because during the maturation phase of the berries in late July-early September, depending upon region, large temperature swings occurring during the increasing daily dark cycle further induce the phenylpropanoid pathway and corresponding production of antioxidant, anthocyanin, proanthocyanidin, and phenolic compounds.

Comparing the anthocyanin profiles of Alaskan berries found in Figure 3 with a cultivated blueberry standard in Figure 4. The magnitude of the detector response on the y-axis fingerprint of the Alaska berry profile is on dehydrated material, not concentrated extract as from standard berries, and is still significantly greater. The concentration of anthocyanins made development of a new gradient system necessary to affect separation, thereby causing different retention times of the compounds.

Comparing the total phenolic profiles of Alaskan berries in Figure 5 to a cultivated blueberry standard in

Figure 6. The magnitude of the detector response on the y-axis differs because the fingerprint of standard berries was from a concentrated extract and the Alaska berry profile is on the dehydrated material that was not  
5 extracted. Note the difference in retention times of the compounds.

Comparing the antioxidant fingerprint profiles of Alaskan berries in Figure 7 to a cultivated blueberry standard in Figure 8. The magnitude of the detector  
10 response on the y-axis differs because the fingerprint of standard berries was from a concentrated extract and the Alaska berry profile is on the dehydrated material that was not extracted. Note the difference in retention times of the compounds.

15 Unlike other berries, the extremely high content of anthocyanins and polyphenols in high latitude berries, exemplified by Alaskan berries, enables the preparation of unique formulations as dehydrated whole foods, compared to others that require extraction to concentrate beneficial  
20 molecules. The berries of the inventive subject matter provide a meaningful dose raw or after only a mild refractance window drying step, without any additional processing or extraction. It should be noted that prior art extracts are produced by processes which require  
25 significant concentration of certain compounds of interest, excluding others naturally occurring in fruits, which do not provide a statistically meaningful dose in raw or simple dried form. The prior art extractions also exclude from the final product other molecules that are  
30 uncharacterized, yet beneficial. In the high latitude berries, exemplified by an Alaskan berry product, all of the substances are retained in essentially natural ratios, and said composition does not require an additional antioxidant element such as vitamin E for effectiveness.

35 As a "base" for product formulation, dehydrated *Vaccinium* rich in hydrophilic antioxidants, could be

enhanced with oils, for example, *Oncorhynchus* (salmon) species, that naturally contain lipophilic Vitamin E and the carotenoid, astaxanthin, and omega-3 fatty acids. Thus, in another aspect of the inventive subject matter, a  
5 composition further comprises an oil from *Oncorhynchus* species.

In order to protect the compositions of the inventive subject matter, to improve delivery convenience, and to improve usability, the compositions of the inventive  
10 subject matter additionally comprise a physiologically acceptable carrier. Thus, in one alternate aspect of the invention, a physiologically acceptable carrier for oral administration in solid, paste, or powder form is selected from the group consisting of a softgel capsule and a two-  
15 piece capsule. In another alternate aspect of the invention, a physiologically acceptable carrier for oral administration in liquid form comprises one or more liquid(s) selected from the group consisting of water, fruit juice, milk, and/or one or more milk derivative(s).  
20 Of course, as will be apparent to one of ordinary skill in the art, such liquid carriers are merely exemplary and may be combined in various interchangeable formulations.

The novel compositions of the invention include a therapeutically effective amount of the active agent  
25 indicated above. This effective amount will generally comprise from about 0.1 mg to about 100 mg of the active agent per kilogram of patient body weight per day. This effective amount can vary depending upon the physical status of the patient and other factors well known in the  
30 art. Moreover, it will be understood that this dosage of active agent can be administered in a single or multiple dosage units to provide the desired therapeutic effect. If desired, other therapeutic agents can be employed in conjunction with those provided by the inventive subject  
35 matter.



The compounds of the invention are preferably delivered to the patient by means of a physiologically acceptable carrier. Such carriers are well known in the art and generally will be in either solid or liquid form. Solid  
5 form preparations which may be prepared according to the inventive subject matter include powders, tablets, dispersible granules, capsules, cachets and suppositories. In general, solid form preparations will comprise from about 5% to about 90% by weight of the active agent.

10 A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders or tablet disintegrating agents; it can also be encapsulating material. In powders, the carrier is a finely divided solid  
15 which is in admixture with the viscous active compound. In tablets, the active compound is mixed with a carrier having the necessary binding properties in suitable proportions and compacted to the shape and size desired. Suitable solid carriers include magnesium carbonate, magnesium stearate,  
20 talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium, carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating  
25 materials as a carrier which may provide a capsule in which the active component, with or without other carriers, is surrounded by carrier, which is thus in association with it. Similarly, cachets are included.

Tablets, powders, cachets, softgels, and capsules can  
30 be used as solid dosage forms suitable for oral administration. If desired for reasons of convenience or patient acceptance, tablets prepared according to the invention may be provided in chewable form, using techniques well known in the art.

35 For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first

melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby to solidify. Liquid form  
5 preparations include solutions, suspensions, and emulsions. As an example may be mentioned water or water/propylene glycol solutions for parenteral injection.

Liquid preparations can also be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions  
10 suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water  
15 with a viscous material, i.e., natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents. Liquid preparations may comprise up to 100% by weight of the subject active agent.

Also contemplated as suitable carriers are solid form  
20 preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions, and emulsions. These particular solid form preparations are most conveniently provided in  
25 unit dose form and as such are used to provide a single liquid dosage unit. Alternately, sufficient solid may be provided so that after conversion to liquid form, multiple individual liquid doses may be obtained by measuring predetermined volumes of the liquid form preparation as  
30 with a syringe, teaspoon, or other volumetric container. When multiple liquid doses are so prepared, it is preferred to maintain the unused portion of said liquid doses at low temperature in order to retard possible decomposition. The solid form preparations intended to be converted to liquid  
35 form may contain, in addition to the active material, flavorants, colorants, stabilizers, buffers, artificial and

natural sweeteners, dispersants, thickeners, solubilizing agents, and the like. The liquid utilized for preparing useful liquid form preparations may be water, isotonic water, ethanol, glycerine, propylene glycol, and the like  
5 as well as mixtures thereof. Naturally, the liquid utilized will be chosen with regard to the route of administration. For example, liquid preparations containing large amounts of ethanol are not suitable for parenteral use.

The preparation may also be in a unit dosage form. In  
10 such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, for example, packeted tablets, capsules, and powders in vials  
15 or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself or it can be the appropriate number of any of these in packaged form.

The preparations of the invention may include one or more preservatives well known in the art, such as benzoic  
20 acid, sorbic acid, methylparaben, propylparaben and ethylenediaminetetraacetic acid. When utilized, preservatives are generally present in amounts up to about 1% and preferably from about 0.05 to about 0.5% by weight of the composition.

Useful buffers for purposes of the invention include  
25 citric acid-sodium citrate, phosphoric acid-sodium phosphate, and acetic acid-sodium acetate in amounts up to about 1% and preferably from about 0.05 to about 0.5% by weight of the composition. Useful suspending agents or  
30 thickeners include cellulosics like methylcellulose, carageenans like alginic acid and its derivatives, xanthan gums, gelatin, acacia, and microcrystalline cellulose in amounts up to about 20% and preferably from about 1% to about 15% by weight of the composition.

35 Sweeteners which may be employed include those sweeteners, both natural and artificial, well known in the

art. Sweetening agents such as monosaccharides, disaccharides and polysaccharides such as xylose, ribose, glucose, mannose, galactose, fructose, dextrose, sucrose, maltose, partially hydrolyzed starch or corn syrup solids  
5 and sugar alcohols such as sorbitol, xylitol, mannitol and mixtures thereof may be utilized in amounts from about 10% to about 60% and preferably from about 20% to about 50% by weight of the composition. Water soluble artificial sweeteners such as saccharin and saccharin salts such as  
10 sodium or calcium, cyclamate salts, acesulfame-K, aspartame and the like and mixtures thereof may be utilized in amounts from about 0.001% to about 5% by weight of the composition.

Flavorants which may be employed in the products of  
15 the invention include both natural and artificial flavors, and mints such as peppermint, menthol, vanilla, artificial vanilla, chocolate, artificial chocolate, cinnamon, various fruit flavors, both individually and mixed, in amounts from about 0.5% to about 5% by weight of the composition.

20 Colorants useful in the inventive subject matter include pigments which may be incorporated in amounts of up to about 6% by weight of the composition. A preferred pigment, titanium dioxide, may be incorporated in amounts up to about 1%. Also, the colorants may include other dyes  
25 suitable for food, drug and cosmetic applications, known as F.D.&C. dyes and the like. Such dyes are generally present in amounts up to about 0.25% and preferably from about 0.05% to about 0.2% by weight of the composition. A full recitation of all F.D.&C. and D.&C. dyes and their  
30 corresponding chemical structures may be found in the Kirk-Othmer Encyclopedia of Chemical Technology, in Volume 5, at pages 857-884, which is accordingly incorporated by reference herein.

Useful solubilizers include alcohol, propylene glycol,  
35 polyethylene glycol and the like and may be used to solubilize the flavors. Solubilizing agents are generally

present. in amounts up to about 10%; preferably from about 2% to about 5% by weight of the composition.

Lubricating agents which may be used when desired in the instant compositions include silicone oils or fluids  
5 such as substituted and unsubstituted polysiloxanes, e.g., dimethyl polysiloxane, also known as dimethicone. Other well known lubricating agents may be employed.

It is not expected that compounds of the inventive subject matter will display significant adverse interactions  
10 with other synthetic or naturally occurring substances. Thus, a compound of the inventive subject matter may be administered in combination with other compounds and compositions useful for the same purposes. In particular the compounds of the inventive subject matter may be  
15 administered in combination with other compounds of the inventive subject matter.

The optimal formulations will be determined by one skilled in the art depending upon considerations such as the route of administration and desired dosage. See, for  
20 example, "Remington's Pharmaceutical Sciences", 18th ed. (1990, Mack Publishing Co., Easton, PA 18042), pp. 1435-1712, the disclosure of which is hereby incorporated by reference. Such formulations may influence the physical state, stability, rate of *in vivo* release, and rate of *in*  
25 *vivo* clearance of the present therapeutic agents of the invention.

#### Route(s) of Administration

The route(s) of administration of the compounds and  
30 compositions of the inventive subject matter are well known to those skilled in the art (see, for example, "Remington's Pharmaceutical Sciences", 18th Edition, Chapter 86, pp. 1581-1592, Mack Publishing Company, 1990). The compounds and compositions may be administered orally, parenterally,  
35 by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir in dosage

formulations containing conventional non-toxic physiologically acceptable carriers, adjuvants, and vehicles. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraperitoneally, 5 intrathecally, intraventricularly, intrasternal, and intracranial injection or infusion techniques.

To be effective therapeutically as central nervous system targets, the compounds and compositions should readily penetrate the blood-brain barrier when peripherally 10 administered. Compounds which cannot penetrate the blood-brain barrier can be effectively administered by an intraventricular route.

The compounds and compositions may be administered in the form of sterile injectable preparations, for example, 15 as sterile injectable aqueous or oleaginous suspensions. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparations may also be sterile injectable solutions or suspensions in 20 non-toxic parenterally-acceptable diluents or solvents, for example, as solutions in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are 25 conventionally employed as solvents or suspending mediums. For this purpose, any bland fixed oil such as a synthetic mono- or di-glyceride may be employed. Fatty acids such as oleic acid and its glyceride derivatives, including olive oil and castor oil, especially in their polyoxyethylated 30 versions, are useful in the preparation of injectables. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants.

Additionally, in another aspect of the inventive subject matter, the compounds and compositions may be 35 administered orally in the form of capsules, tablets, aqueous suspensions, or solutions. Tablets may contain

carriers such as lactose and corn starch, and/or lubricating agents such as magnesium stearate. Capsules may contain diluents including lactose and dried corn starch. Aqueous suspensions may contain emulsifying and suspending agents  
5 combined with the active ingredient. The oral dosage forms may further contain sweetening, flavoring, coloring agents, or combinations thereof. Delivery in an enterically coated tablet, caplet, or capsule, to further enhance stability and provide release in the intestinal tract to improve  
10 absorption, is the best mode of administration currently contemplated.

The compounds may also be administered rectally in the form of suppositories. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient  
15 which is solid at room temperature, but liquid at rectal temperature and, therefore, will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycols.

Furthermore, the compounds may be administered  
20 topically, especially when the conditions addressed for treatment involve areas or organs readily accessible by topical application, including the lower intestinal tract. Suitable topical formulations can be readily prepared for such areas or organs. For example, topical application to  
25 the lower intestinal tract can be effected in a rectal suppository formulations (see above) or in suitable enema formulations.

It is envisioned that the continuous administration or sustained delivery of the compounds and compositions of the  
30 inventive subject matter may be advantageous for a given condition. While continuous administration may be accomplished via a mechanical means, such as with an infusion pump, it is contemplated that other modes of continuous or near continuous administration may be  
35 practiced. For example, such administration may be by subcutaneous or muscular injections as well as oral pills.

Techniques for formulating a variety of other sustained- or controlled-delivery means, such as liposome carriers, bio-erodible particles or beads and depot injections, are also known to those skilled in the art.

5

#### Dosage

For nutraceutical preparations, at least 1.5 mm dietary ORAC unit intake from substances occurring naturally in *Vaccinium* must comprise a single dose. Phytopharmaceutical  
10 preparations, designed to manage or treat a specific clinical condition, must contain at least 1.5 mm ORAC unit intake, calculated from the average concentrations and molecular weight of anthocyanin, polyphenolic, or proanthocyanidin molecules contained in the whole berry  
15 product or in specific extracts. Depending upon the condition being treated, dried or extracted preparations may contain up to 1500 mm ORAC unit intake from any or all of the anthocyanin, polyphenolic or proanthocyanidin molecules, or other active ingredients.

20 For phytopharmaceutical and pharmaceutical substances, dosage levels on the order of about 0.1 mg to about 100 mg per kilogram body weight of the active ingredient compositions are useful in the treatment of the above conditions, with preferred levels ranging on doses for  
25 reference man of 70 kg, from 7 mg per day to 7 g per day. For children under twelve, proportional doses reflecting body weight would be utilized. The compounds and compositions of the inventive subject matter may usually be given in two or three doses daily. Starting with a low dose  
30 once or twice daily and slowly working up to higher doses if needed is a preferred strategy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

35 It is understood, however, that a specific dose level for any particular patient will depend upon a variety of



factors, including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the rate of excretion; drug combination; the severity of the particular disorder being treated; and the form of administration. One of ordinary skill in the art would appreciate the variability of such factors and would be able to establish specific dose levels using no more than routine experimentation.

Thus, the inventive subject matters also relates to a composition comprising berries obtained from one or more plant species of the genus *Vaccinium*, wherein said plant(s) is/are processed according to the following steps:

- (a) Exposed to one or more uninterrupted photoperiod(s) of at least about 18 hours to 24 hours per day for about 60 days during flowering and fruit setting;
- (b) Exposed to one or more uninterrupted photoperiod(s) of at least about 15 hours per day for about 30 days during fruit ripening and maturity;
- (c) Grown at least about 7 days past peak fruit ripeness;
- (d) Dried; and
- (e) Formulated into a therapeutic or nutritional composition having about 0.1 mg to about 100 mg per kilogram body weight of active ingredients.

#### **Methods for Using the Inventive Compositions**

The present invention relates to a method for treating a disorder in an animal, which comprises administering to said animal an effective amount of a composition comprising one or more berries, leaves, roots, and/or root barks obtained from one or more plant species of the genus *Vaccinium*,

wherein said plant(s) is/are grown under the

following conditions:

- i. Subject to one or more uninterrupted photoperiod(s) of at least about 18 hours to 24 hours per day for about 60 days during flowering and fruit setting; and
  - ii. Subject to one or more uninterrupted photoperiod(s) of at least about 15 hours per day for about 30 days during fruit ripening and maturity;
- and wherein said disorder is selected from the group consisting of diabetes mellitus, inflammatory disorders, ulcers, viral diseases or disorders, microbial diseases or disorders, interstitial fluid formation, capillary resistance and permeability, decreased platelet aggregation, eyestrain, diabetic retinopathy, macular degeneration, cataracts, glaucoma, cancer, obesity, atherosclerosis, and cardiovascular disease; for improving visual function by promoting dark adaptation, enhancing the activity of metabolic enzymes in the retina, improving retinal regeneration, improving visual acuity, night vision, and contrast sensitivity; and for promoting wound-healing, normal formation of connective tissue, and strengthening of capillaries.

In another aspect of the inventive subject matter, a nutraceutical would be prepared from berries processed under any of the conditions described above, would be used alone for treatment of any of the aforementioned conditions.

In another aspect of the inventive subject matter, a nutraceutical would be prepared from berries processed under any of the conditions described above would be used in combination with *Oncorhynchus* oil for treatment of any of the aforementioned conditions.

In an alternate aspect of the inventive subject matter, a nutraceutical would be prepared from berries processed under any of the conditions described above would be used as a foundation, with out without *Oncorhynchus* oil, and with

other appropriate substances for treatment of any of the aforementioned conditions.

In another aspect of the inventive subject matter, a nutraceutical would be prepared from berries with any or all combinations of leaves, stems, and roots and root bark processed under any of the conditions described above would be used alone for treatment of any of the aforementioned conditions.

In another aspect of the inventive subject matter, a nutraceutical would be prepared from berries with any or all combinations of leaves, stems, and roots and root bark processed under any of the conditions described above would be used in combination with *Oncorhynchus* oil for treatment of any of the aforementioned conditions.

In an alternate aspect of the inventive subject matter, a nutraceutical would be prepared from berries with any or all combinations of leaves, stems, and roots and root bark processed under any of the conditions described above would be used as a foundation, with out without *Oncorhynchus* oil, and with other appropriate substances for treatment of any of the aforementioned conditions.

Expected Health Benefits. In order to determine if there are health implications, one needs to understand 1) what phytochemicals in the fruit are responsible for the ORAC activities measured, 2) whether these substances can be absorbed, and 3) what physiological responses might be altered following their absorption.

Cancer: Fruits and vegetables contribute micronutrients such as ascorbic acid, beta carotene, and myriad other phytochemicals with antioxidant properties; the more closely a micronutrient was correlated with total vegetable and fruit intake, the more it appeared protective against cancer. A substantial body of experimental work has established that flavonoids can suppress carcinogenesis in animal models and there is considerable interest in the biological effects of these compounds at the cellular level.

The consumption of antioxidant-rich fruits and vegetables has been associated with lower incidence and lower mortality rates of cancer in several human cohort and case-control studies for all common cancer sites. Steinmetz  
5 and Potter reviewed the scientific literature from 206 human epidemiological studies and 22 animal studies on the relationship between vegetable and fruit consumption and the risk of cancer.

Evidence for a protective effect of greater vegetable  
10 and fruit consumption is consistent for cancers of the stomach, esophagus, lung, oral cavity and pharynx, endometrium, pancreas and colon. In an earlier review, approximately 200 studies were compiled and examined for the relationship between fruit and vegetable intake and cancers  
15 of the lung, colon, breast, cervix, esophagus, oral cavity, stomach, bladder, pancreas and ovary. For most cancer sites, individuals with low fruit and vegetable intake experienced about twice the risk of cancer compared with those with high intake. A statistically significant protective effect of  
20 fruit and vegetable consumption was found in 128 of 156 dietary studies in which results were expressed in terms of relative risk. Thus, the scientific evidence regarding a role for vegetable and fruit consumption in cancer prevention is generally consistent and is supportive of  
25 current dietary recommendations.

However, what is not clear from the available literature is what phytochemicals or antioxidants are responsible for the anticarcinogenicity and if specific fruits or vegetables might be more effective than others in  
30 preventing age-related diseases. The potentially antineoplastic effects of flavonoids not only include antioxidant activity, but induction of Phase II enzyme activity, inhibition of protein kinases and interactions with Type II estrogen binding sites. Flavonoids interact  
35 with cellular signal pathways controlling the cell cycle, differentiation and apoptosis.

Cardiovascular Disease: Epidemiological data, human clinical trials, and animal studies suggest that dietary antioxidants and diets rich in vegetables and fruits decrease cardiovascular disease and increase longevity.

5 Consistent with the observed cancer chemoprotective effect, a highly significant negative association between intake of total fresh fruits and vegetables and ischemic heart disease mortality was reported in Britain and in the United States. A significant negative association was also reported between

10 fruit and vegetable consumption and cerebrovascular disease mortality. The protective effects appear to be synergistic and are optimal when an array of different antioxidants are consumed simultaneously in naturally occurring quantities from different dietary plant sources.

15 The Anticipated Health Benefits of Anthocyanin Pigments and Polyphenolics. There is considerable anecdotal, animal, and epidemiological evidence that dietary flavanoids, including anthocyanins, proanthocyanidins, and various polyphenolics are expected to have preventive and

20 therapeutic roles in a number of human diseases. Thus, naturally occurring polyphenolic compounds appear to have considerable potential for nutraceuticals and pharmaceutical uses as chemopreventive agents against neoplastic changes in the alimentary tract.

25 Anthocyanins. Anthocyanin pigments are responsible for the red, purple, and blue colors of many fruits, vegetables, cereal grains, and flowers. They have been the subject of investigation by botanists and plant physiologists because of their roles as pollination attractants and

30 phytoprotective agents, and have been very useful in taxonomic studies. Food scientists and horticulturists continue to study these compounds because of their obvious importance to the color quality of fresh and processed fruits and vegetables. Over 300 structurally distinct

35 anthocyanins have been identified in nature. Flavonols, flavan-3-ols, flavones, flavanones, and flavanonols are

additional classes of flavonoids that differ in their oxidation state from the anthocyanins.

Other phenolic compounds. The polyphenolic profile of fruits and fruit juices is likely to include flavonols, free  
5 and esterified phenolic acids, and procyanthocyanidins or polymeric tannins. At least 5,000 naturally occurring polyphenolics have been identified, including over 2,000 flavonoids. Polyphenolics also contribute to food and beverage color. Proanthocyanidins and condensed tannins  
10 provide astringency and bitterness in tea and wine.

Early studies with rats suggest this antioxidant power from fruits translates to protection of cells and tissues. Dietary supplementation to rats of an extract from blueberries or strawberries has been shown to protect  
15 against the oxidative stress caused by 100% oxygen exposure.

The in vitro antiradical activity of anthocyanins and polyphenolics present in crude extracts of *Ribes*, *Rubus*, and *Vaccinium* genera on chemically-generated superoxide radicals as well as the inhibitory activity towards the enzyme  
20 xanthine oxidase have been studied. All the crude extracts demonstrated a remarkably high activity towards chemically-generated superoxide radicals. The activities were greater than those expected on the basis of the quantities of anthocyanins and polyphenolics present in the samples. All  
25 showed a certain inhibitory activity towards xanthine oxidase.

A number of studies have shown that mortality from coronary heart disease is inversely correlated with intake of flavonoids in the diet. Flavonoids are expected to also  
30 help prevent strokes. Through the much publicized "French paradox", the public has become aware that certain populations of red-wine drinkers in France and Italy have much lower rates of coronary heart disease than their North American and Northern European counterparts. It is widely  
35 accepted that red wine phenolics contribute at least partly to this beneficial effect. Experts have suggested that a

recommended minimum daily requirement for dietary antioxidants be established.

Beneficial Properties of *Vaccinium* species. Bilberry and blueberry fruits of the *Vaccinium* genus are a rich source of anthocyanosides, a group of red to blue plant pigments, which exist as condensed products, for example glycosides, of anthocyanins known as anthocyanidins, combined usually with sugar(s) such as glucose, arabinose, and galactose. The 3-glucoside(s) and 3-galactoside(s) of delphinidin, malvidin, petunidin, cyanidin, and peonidin are the primary anthocyanins that have been identified in bilberries and blueberries.

The health-promoting effects of *Vaccinium* berries are likely accounted for primarily by the anthocyanins, but other polyphenols and phenolic acids, proanthocyanidins, and various flavonoid compounds are present in considerable concentrations. Anthocyanins are expected to have potential health benefits that are both independent of or in addition to their antioxidant effects, and most of the components present within *Vaccinium* are expected to have multiple health benefits which have not been well elucidated.

Bilberry. One of the most widely used *Vaccinium* supplements worldwide comes from *V. myrtillus*, a shrubby perennial that grows in the woods and forest meadows of Northern Europe and Asia, and to a lesser extent, in North America. *V. myrtillus* is a close relative of common North American species of commerce that include *V. angustifolium*, *V. corymbosum*, and *V. macrocarpon*. *V. myrtillus* has small, blue-black fruit and differs from an American blueberry in that its meat is also blue-black.

*V. myrtillus* scores highest among 50 fruits and vegetables in its ability to defuse damaging oxygen free radicals in the ORAC assay. In vitro assays show that bilberry extracts are expected to have an anticancer role from ability to induce the Phase II xenobiotic

detoxification enzyme quinone reductase. The majority of inducer potency was contained in a hexane/chloroform subfraction, as opposed to the hydrophilic fraction rich in anthocyanins.

- 5           The leaf of the bilberry plant has also been used as a component of "diabetic" teas and is a rich source of chromium. High doses of bilberry leaves, greater than 480 mg/day, can be toxic. Traditional medicine tends to favor simple preparations of *V. myrtillus* that are not used in
- 10 conjunction with other substances. Patent preparations typically contain a number of different components to enhance the value of *V. myrtillus*. An antihyperglycemic effect of the Antidiabetis herbal preparation containing "Myrtilli folium" as the principal ingredient has been
- 15 demonstrated to lower blood glucose and fructosamine levels in alloxan-induced non-obese diabetic mice. In streptozotocin-induced diabetic rats, active constituent(s) of *V. myrtillus* leaves were found to consistently lower plasma glucose levels and to lower plasma triglyceride
- 20 levels associated with dyslipidemia in diabetics. Another patent formulation uses Valerian root, *Valeriana officianalis*, either alone or in combination with other plant components, to be effective in lowering or otherwise regulating blood glucose concentrations.
- 25           The berries or extracts of the berries are believed to offer even greater benefit than the tea. Flavonoids, myrtillin and myricetin, and possibly other polyphenolics and tannins of bilberries have been shown to lower blood glucose. To determine the health-promoting effects of
- 30 bilberry fruits several studies have been undertaken with a highly purified extract of *V. myrtillus* L., standardized to 36% anthocyanosides. In addition to its antioxidant activity, Myrtocyan<sup>R</sup> has been shown to 1) prevent or control interstitial fluid formation and contribute to controlling
- 35 the blood flow redistribution in the microvascular network, 2) modulate capillary resistance and permeability, 3)



improve visual function by promoting dark adaptation after dazzling, 4) promote wound-healing, 5) attenuate blood vessel thickening, such as atherosclerosis, and 6) possess anti-ulcer activity. Others corroborate that bilberry  
5 anthocyanosides are responsible for normal formation of connective tissue and strengthening of capillaries in the body, decreased platelet aggregation, and improved retinal regeneration.

Alterations in the capillary filtration of  
10 macromolecules are well documented in diabetic patients and experimental diabetes. Various flavonoids including anthocyanosides have been shown to be effective against experimentally induced capillary hyperfiltration. In *V. myrtillus* anthocyanoside treated streptozotocin-diabetic  
15 rats, interstitial albumin retention and the ratio of the amplitudes of the low- and high-frequency peaks, an index of lymphatic function were measured. Anthocyanosides appeared to be effective in preventing the increase in capillary filtration of albumin and the failure of lymphatic  
20 uptake of interstitial albumin in diabetic animals.

Bilberry anthocyanosides have been shown to improve symptoms and complications of IDDM and NIDDM related to the macrovasculature and microvasculature. A positive influence of bilberry anthocyanosides on the permeability and tendency  
25 of retinal microvasculature to hemorrhage has been observed. Diabetic retinopathy and macular degeneration that can lead to blindness is due to an abnormally increased synthesis of connective tissue in order to a) repair leaking capillaries and b) formation of new capillaries. Anthocyanosides help  
30 to prevent diabetics from injuries caused by malfunction of synthesis-activities throughout normal diabetic medical treatment such as laser coagulation therapy.

Anthocyanosides are expected also to improve vision by enhancing the activity of metabolic enzymes in the retina.  
35 Diabetic cataracts are caused by an elevation of polyols within the lens of the eye catalyzed by the enzyme aldose

reductase. Bilberry is expected to diminish or help prevent cataracts through its flavonoids, particularly quercetin and derivatives, which are potent inhibitors aldose reductase. In addition, pathophysiological mechanisms of cataract  
5 formation include deficient glutathione levels contributing to a faulty antioxidant defense system within the lens of the eye. Similar to patients with cataracts, those with glaucoma typically have compromised antioxidant defense systems, and are expected to benefit from anthocyanoside  
10 supplements.

Bilberry anthocyanosides enhance the regeneration of rhodopsin or visual purple, an eye protein necessary for vision in dim light or at night, and have been used to improve visual acuity and night vision. Although a report  
15 of improved night vision among air traffic controllers supports these claims, other recent well-controlled clinical trials did not show any benefit on night visual acuity or contrast sensitivity in subjects with normal vision.

Blueberry. Research is showing that blueberries contain  
20 a number of compounds that have medicinally beneficial properties. The earliest recorded use of blueberry for medicinal purposes dates from the Middle Ages, and it has been used in European folk medicine since the 16th century. Some of its reported medicinal benefits include antioxidant  
25 properties, anti-cancer activity, reducing heart disease risk, strengthening collagen, regulating blood sugar, improving night vision, preventing urinary tract infections, reducing replication of the HIV virus, and treating diarrhea. Blueberry leaf tea has a long history as a folk  
30 treatment for diabetes and, in animal studies, extracts from leaves decreased blood glucose and blood triglyceride levels. In normal and diabetic dogs, oral administration reduces hyperglycemia, even when glucose is injected intravenously at the same time.

35 Crude extracts of lowbush blueberry, and other *Vaccinium* species such as cranberry and lingonberry, are

active inhibitors of the cell division regulatory enzyme, ornithine decarboxylase activity. The greatest activity in these extracts appeared to be contained in the polymeric proanthocyanidin fractions of the lowbush blueberry. The  
5 anthocyanidin and ethyl acetate extracts of these *Vaccinium* species, as well as bilberry, are either inactive or relatively weak inhibitors of ornithine decarboxylase activity. Proanthocyanidins from blueberry, as well as cranberry, are also effective inhibitors of *Escherichia coli*  
10 adhesion factor and help to prevent urinary tract infections.

A blueberry extract was examined in a Japanese study for effects on eyestrain and fatigue. Researchers employed critical fusion frequency of flicker test involving rapid  
15 light flickering in front of the patient to determine how quickly the eye adjusts, and a visual analogue scale to rank the degree to which the eyes are tired. Blueberry extract had a positive effect on tired eyes more than on any other symptom.

20 In experimental hyperoxia in rats, a redistribution of systemic antioxidants between serum and pleural effusion and an increase in capillary permeability occurs. Of various fruits and vegetable extracts tested, only the blueberry extract was effective in alleviating the hyperoxia-induced  
25 redistribution of antioxidants between tissues. Dietary consumption of polyphenolics from blueberries was found to enhance significantly red blood cell resistance to hydrogen peroxide, 100 mM, induced reactive oxygen species production.

30 Research that indicates increasing vulnerability to oxidative stress with aging, leading to cancer and cardiovascular disease, also demonstrates that age-related declines in neuronal and cognitive function and development of neurodegenerative diseases such as Alzheimer's disease  
35 or vascular dementia may be superimposed upon a vulnerable neuronal environment. Among the most effective agents that

antagonized neuronal cell OSV are multiple polyphenolics found in blueberry extract, and other fruits, with high antioxidant activity.

5                    **Products Produced by the Process of**  
                      **The Inventive Subject Matter**

The present invention further relates to a product produced by the process of:

10            i. Growing a plant of a species of the genus *Vaccinium* under the following conditions:

(a) Subject to one or more uninterrupted photoperiod(s) of at least about 18 hours to 24 hours per day for about 60 days during flowering and fruit setting,

15            (b) Subject to one or more uninterrupted photoperiod(s) of at least about 15 hours per day for about 30 days during fruit ripening and maturity, and

20            (c) Grown at least about 7 days past peak fruit ripeness;

ii. Harvesting berries, leaves, roots, and/or root barks from said plant; and

iii. Drying said berries, leaves, roots, and/or root barks from said plant.

25            In another aspect of the inventive subject matter, the growing step and/or the harvesting step of said process additionally comprises exposing said plant(s) to one or more freeze cycle(s) during growth and/or post-harvest.

30            In another aspect of the inventive subject matter, the harvesting and drying steps are limited to the berries of said plant(s).

**EXAMPLES**

35            The following examples are illustrative of the inventive subject matter and are not intended to be

limitations thereon. Unless otherwise indicated, all percentages are based upon 100% by weight of the final composition.

5

**EXAMPLE 1****Preparation of Berry Compositions**

The following example illustrates the preparation of a preferred active agent in several compositions provided according to the inventive subject matter.

10 Mature, high latitude berries of the genus *Vaccinium* are collected from wild stands. Samples of plant material from each of the stands are retained for a voucher specimen. The berries are frozen for a minimum duration of 24 hours prior to further processing. Frozen berries and juice  
15 extruded during thaw are ground together to form a thick, spreadable puree. The puree is applied to the conveyor belt of a Refractance Window dryer for evaporation. The resulting granular material is used directly or is further processed for various product requirements.

20 For use in functional foods, the granular material is incorporated into products including but not limited to bakery goods and breakfast, snack, sports, calorie-reduced and meal replacement bars, breakfast cereals, dairy-based products, frozen fruit products, jams, jellies, syrups,  
25 sauces, and condiments.

For use in dietary supplements, the granular material is milled to a sufficiently fine powder for respective applications including but not limited to fruit and berry-based beverages, such as tonics, sports drinks, and health-  
30 related beverages, in tablets or chews, and for filling softgel and 2-piece hard shell capsules.

For use as a phytopharmaceutical or for management of specific disease states, the milled powder may be used alone or formulated with other ingredients. The fresh berries and  
35 derivative granular or milled powder, leaves, stems, bark, roots, and root barks may also be extracted to concentrate

certain components for prevention or management of specific disease conditions.

For use as a pharmaceutical, the fresh berries and granular material or milled powder comprised of berries, flowers, leaves, stems, bark, roots, and root barks may be extracted for preparation of pure, novel, small molecules with specific therapeutic properties.

#### EXAMPLE 2

10

##### Treating Diabetes

The following example illustrates use of a composition provided according to the inventive subject matter for treating Type I Diabetes.

A composition of the inventive subject matter was given to a diabetic individual with instructions to consume 1 teaspoon in the morning at fasting, and then to monitor blood glucose within the hour. The blood glucose levels at fasting of said individual normally run 120-140 mg/dl. On three separate occasions, said individual reported a drop to 35, 27, and less than 12 mg/dl, respectively.

#### EXAMPLE 3

##### Treating Hyperglycemia

A patient presents for treatment of hyperglycemia. The patient is administered an inventive composition having an effective amount of myricetin and its glucoside, documented hypoglycemic agents which are significant components of said composition. The patient undergoes the procedure well, without complication, and the inventive composition is successful in reducing blood sugar, avoiding more complex, expensive, and potentially side-effect-producing treatment.

**EXAMPLE 4****Vaccinium Extracts**

The fresh or dried leaves of *Vaccinium* species are boiled to extract water-soluble substances to make a  
5 decoction, or are steeped or soaked without boiling to extract water-soluble substances to make an infusion. The resulting decoctions and infusions are used as a urinary tract antiseptic, anti-tubercular agent, and hypoglycemic agent. Applicant expects that the leaves are most potent  
10 when the plant is in flower, and that ORAC values are higher at that time for leaves; it is believed that polyphenolics contribute to potency and high ORAC values.

The invention being thus described, it will be obvious  
15 that the same may be modified or varied in many ways. Such modifications and variations are not to be regarded as a departure from the spirit and scope of the invention and all such modifications and variations are intended to be included within the scope of the following claims.

**WE CLAIM:**

1. A composition comprising:
  - i. one or more berries, leaves, roots, and/or root  
5 barks obtained from one or more plant species of the genus *Vaccinium*, wherein said plant(s) is/are grown under the following conditions:
    - (a) Subject to one or more uninterrupted  
10 photoperiod(s) of at least about 18 hours to 24 hours per day for about 60 days during flowering and fruit setting; and
    - (b) Subject to one or more uninterrupted  
15 photoperiod(s) of at least about 15 hours per day for about 30 days during fruit ripening and maturity.
2. The composition of claim 1, wherein said plant(s) is/are grown at least about 7 days past peak fruit ripeness.
- 20 3. The composition of claim 1, wherein said growing conditions comprise growth of said plant(s) at a latitude greater than 55 degrees north or south of the equator of the Earth.
- 25 4. The composition of claim 3, wherein said growing conditions comprise growth of said plant(s) at a latitude greater than 66 degrees north or south of the equator of the Earth.
- 30 5. The composition of claim 1, wherein said conditions additionally comprise the step of exposing said plant(s) to one or more freeze cycle(s) during growth and/or post-harvest.
- 35 6. The composition of Claim 1, comprising the additional step of drying said berries, leaves, roots,



and/or root barks.

7. The composition of Claim 6, wherein said drying step is a refractance window drying process.

5

8. The composition of Claim 6, wherein said dried berries, leaves, roots, and/or root barks do not require an additional processing or extraction step.

10

9. The composition of claim 1, wherein said one or more plant species of the genus *Vaccinium* are selected from the group consisting of *V. alaskensis*, *V. axillare*, *V. caespitosum*, *V. caespitosum* var. *paludicola*, *V. membranaceum*, *V. parvifolium*, *V. ovalifolium*, *V. oxycoccus*,  
15 *V. shikokianum*, *V. uliginosum* subsp. *alpinum*, *V. uliginosum* var. *salicinum*, *V. uliginosum* subsp. *microphyllum*, *V. vitis-idaea* subsp. *minus*, *V. vitis-idaea* subsp. *vitis-idaea*.

20

10. The composition of claim 1, wherein said composition comprises berries of said plant(s).

11. The composition of Claim 1, wherein said composition does not require an additional antioxidant element for effectiveness.

25

12. The composition of Claim 1, further comprising an oil from *Oncorhynchus* species.

13. The composition of Claim 1, additionally  
30 comprising a physiologically acceptable carrier.

14. The composition of Claim 13, wherein said physiologically acceptable carrier is selected from the group consisting of a softgel capsule and a two-piece  
35 capsule.

15: The composition of Claim 13, wherein said physiologically acceptable carrier comprises one or more liquid(s) selected from the group consisting of water, fruit juice, milk, and/or one or more milk derivative(s).

5

16. A method for treating a disorder in an animal, which comprises administering to said animal an effective amount of a composition comprising one or more berries, leaves, roots, and/or root barks obtained from one or more  
10 plant species of the genus *Vaccinium*,

wherein said plant(s) is/are grown under the following conditions:

i. Subject to one or more uninterrupted photoperiod(s) of at least about 18 hours to 24  
15 hours per day for about 60 days during flowering and fruit setting; and

ii. Subject to one or more uninterrupted photoperiod(s) of at least about 15 hours per day for about 30 days during fruit ripening and  
20 maturity;

and wherein said disorder is selected from the group consisting of diabetes mellitus, inflammatory disorders, ulcers, viral diseases or disorders, microbial diseases or disorders, interstitial fluid formation, capillary  
25 resistance and permeability, decreased platelet aggregation, eyestrain, diabetic retinopathy, macular degeneration, cataracts, glaucoma, cancer, obesity, atherosclerosis, and cardiovascular disease; for improving visual function by promoting dark adaptation, enhancing the activity of  
30 metabolic enzymes in the retina, improving retinal regeneration, improving visual acuity, night vision, and contrast sensitivity; and for promoting wound-healing, normal formation of connective tissue, and strengthening of capillaries.

35

17. The method of claim 16, wherein said plant(s) is/are grown at least about 7 days past peak fruit ripeness.

18. The method of claim 16, wherein said conditions  
5 comprise growth of said plant(s) at a latitude greater than 55 degrees north or south of the equator of the Earth.

19. The method of claim 18, wherein said conditions  
10 comprise growth of said plant(s) at a latitude greater than 66 degrees north or south of the equator of the Earth.

20. The method of claim 16, wherein said conditions  
15 additionally comprise the step of exposing said plant(s) to one or more freeze cycle(s) during growth and/or post-harvest.

21. The method of claim 16, comprising the additional  
20 step of drying said berries, leaves, roots, and/or root barks.

22. The method of claim 21, wherein said drying step  
is a refractance window drying process.

23. The method of claim 21, wherein said dried  
25 berries, leaves, roots, and/or root barks do not require an additional processing or extraction step.

24. The method of claim 16, wherein said one or more  
30 plant species of the genus *Vaccinium* are selected from the group consisting of *V. alaskensis*, *V. axillare*, *V. caespitosum*, *V. caespitosum* var. *paludicola*, *V. membranaceum*, *V. parvifolium*, *V. ovalifolium*, *V. oxycoccus*, *V. shikokianum*, *V. uliginosum* subsp. *alpinum*, *V. uliginosum* var. *salicinum*, *V. uliginosum* subsp. *microphyllum*, *V. vitis-idaea* subsp. *minus*, *V. vitis-idaea* subsp. *vitis-idaea*.  
35

25. The method of claim 16, wherein said composition comprises berries of said plant(s).

26. The method of claim 16, wherein said composition additionally comprises an oil from *Oncorhynchus* species.

27. A product produced by the process of:

i. Growing a plant of a species of the genus *Vaccinium* under the following conditions:

(a) Subject to one or more uninterrupted photoperiod(s) of at least about 18 hours to 24 hours per day for about 60 days during flowering and fruit setting,

(b) Subject to one or more uninterrupted photoperiod(s) of at least about 15 hours per day for about 30 days during fruit ripening and maturity, and

(c) Grown at least about 7 days past peak fruit ripeness;

ii. Harvesting berries, leaves, roots, and/or root barks from said plant; and

iii. Drying said berries, leaves, roots, and/or root barks from said plant.


28. The product produced by the process of Claim 27, wherein the growing step and/or the harvesting step of said process additionally comprises exposing said plant(s) to one or more freeze cycle(s) during growth and/or post-harvest.

29. The product produced by the process of Claim 27, wherein the harvesting and drying steps are limited to the berries of said plant(s).

30. A composition comprising berries obtained from one or more plant species of the genus *Vaccinium*, wherein said plant(s) is/are processed according to the following steps:

- (a) Exposed to one or more uninterrupted photoperiod(s) of at least about 18 hours to 24 hours per day for about 60 days during flowering and fruit setting;
- 5 (b) Exposed to one or more uninterrupted photoperiod(s) of at least about 15 hours per day for about 30 days during fruit ripening and maturity;
- (c) Grown at least about 7 days past peak fruit  
10 ripeness;
- (d) Dried; and
- (e) Formulated into a therapeutic or nutritional composition having about 0.1 mg to about 100 mg per kilogram body weight of active ingredients.

Figure 1




Hydrophilic ORAC ranking of fruits

Figure 2

		ORAC <sub>hydro</sub>	ORAC <sub>lipo</sub>	ORAC <sub>total</sub> (mmoleTE/g)	ORAC <sub>HO</sub> (mmoleGA/g)	ORAC <sub>ONOO</sub> (mmoleTE/g)
5	Alaska blueberry	1,160	45	1,205	190	226
	Cultivated blueberry-1	155	N/D	N/D	5	45
	Cultivated blueberry-2	N/D	N/D	N/D	90	125
	Cultivated blueberry-3	N/D	N/D	N/D	95	98
	Wild blueberry	314	N/D	N/D	145	50
10	Bilberry	330-698*	N/D	330-698*	170	N/D
	Vitamin C (pure)	5,513	N/A	5,513	0	N/A
	Vitamin E (pure)	N/A	1,563	1,563	0	N/A

N/A = Not applicable; N/D = Not determined; \* = Values from the literature


Figure 3




Separation of 10 common anthocyanins using RP-HPLC with UV  
detection. The structure of each compound was characterized  
5 by the Finningan LCQ Mass spec detector.



Figure 4



HPLC Chromatogram of Anthocyanins Separation



Malvidin: R1=OCH3, R2=OCH3; Petunidin: R1=OCH3, R2=OH


Peonidin: R1=OCH3, R2=H; Delphinidin: R1=OH, R2=OH

Cyanidin: R1=OH, R2=H

Identity of Anthocyanin Peak and its Mass Spec Data

Anthocyanin	Retention Time	Molecular Ion	Product Ion (aglycone)
delphinidin-3-galactoside	7.095	465	303
delphinidin-3-glucoside	7.525	465	303
cyanidin-3-galactoside	8.249	449	287
cyanidin-3-glucoside	8.766	449	287
petunidin-3-galactoside	8.984	479	317
cyanidin-3-arabinoside	9.623	419	287
petunidin-3-coumarate	10.550	481	317
petunidin-3-arabinoside	10.771	449	317
peonidin-3-galactoside	10.771	463	301
peonidin-3-glucoside	11.631	463	301
malvidin-3-galactoside	11.631	493	331
malvidin-3-glucoside	12.695	493	331
malvidin-3-arabinoside	14.185	463	331

Figure 5



HPLC chromatogram (280 nm) of Alaskan Blueberries-wild Ethyl Acetate Fraction

Figure 6





Figure 6. HPLC Chromatogram for Phenolic Profile

Table 2. Identity of Phenolic Peak and its Mass Spec Data

Peak	Retention Time	[M+1] <sup>+</sup>	[M-1] <sup>-</sup>	MW	Structure
1	6.06		153	154	Protocatechuic acid
2	6.55		153	154	Gentisic acid
3	9.26		289	290	Catechin
4	9.78		353	354	Chlorogenic acid
5	17.87	321	319	320	unknown
6	18.86		864	865	Trimeric proanthocyanidin A
7	19.74	481	479	480	Myricetin-3-glucoside
8	21.07	465	463	464	Quercetin-3-glucoside
9	21.44	479	477	478	Tamarixetin-3-glucoside
10	22.59	435	433	434	Quercetin-3-arabinoside
11	22.86	509	507	508	Syringetin-3-glucoside
12	24.30		347	348	unknown
13	24.71	319	317	318	Myricetin
14	25.93		445	446	unknown
15	27.96	303	301	302	Quercetin


Separation and characterization of phenolic compounds using RP-HPLC with UV detection.

Figure 7




Antioxidant Fingerprint for Alaskan Blueberries-wild  
obtained by multi-channel ECD Detector

Figure 8



Antioxidant fingerprint of blueberries obtained by the ESA 8-channel electron chemical detector. Each peak in the chromatogram represents an antioxidant component.


Figure 9



Rank of Antioxidant Activity Against Hydroxyl Radicals of fruits

10/47

Figure 10



The profile of the proanthocyanins from Alaskan Blueberries. B1 are epicatechin and catechin. Peaks B2 through B7 stand for the B type procyanidin from dimers to heptamers. A2 and A3 are dimers and trimers with one A type inter-flavan linkage as reflected by the mass spectra. When compared to other blueberries, Alaskan Blueberries contains substantial high level of A2 dimers.


Proanthocyanidins	Alaska Blueberry	*Blueberry	Cocoa	Cranberry
monomers	0.37	0.18	0.65	0.48
dimers	1.10	0.46	0.84	1.53
trimers	1.16	0.38	1.03	1.44
tetramers	1.22	0.5	1.24	1.46
pentamers	1.27	0.47	1.41	1.39
hexamers	1.51	0.69	1.84	2.04
heptamers	1.05	0.48	1.13	1.56
octamers	1.06	0.61	1.19	2.17
nonamers	1.49	0.93	1.59	NA
decamers	0.71	NA	0.74	NA
polymers	24.49	15.28	9.81	20.58
Total (mg/g)	35.43	19.99	21.48	32.65

10 Proanthocyanidin content of Alaska blueberry, blueberry, cocoa, and cranberry.

**6 BB LEAVES #3 EtOAc**

about 25ug on column

Sequence:	25JAN02	Injection Volume:	5.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BA6	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/28/02 14:34	Sample Amount:	1.0000
Run Time (min):	30.00		



No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	


Figure 11



**6 BB STEMS #3 EtOAc**

about 100ug on column

Sequence:	03JAN02	Injection Volume:	5.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BA6	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/3/02 15:51	Sample Amount:	1.0000
Run Time (min):	30.01		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 12

**6 BB STALKS #3 EtOAc**

about 100ug on column

Sequence:	04Jan02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	GA6	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/4/02 14:54	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	RetTime min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 13

**16 BB ROOT #3 EtOAc**

about 80ug on column

Sequence:	03Jan02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BB5	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/3/02 21:31	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 14

**2 BB LEAVES #1Hexane**

about 25ug on column

Sequence:	25JAN02	Injection Volume:	5.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BA2	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/28/02 11:22	Sample Amount:	1.0000
Run Time (min):	30.01		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 15

**3 BB LEAVES #1b DCM fraction**

about 25ug on column

Sequence:	25JAN02	Injection Volume:	5.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BA3	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/28/02 12:10	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 16

**4 BB LEAVES #2 DCM**

about 25ug on column

Sequence:	25JAN02	Injection Volume:	5.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BA4	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/28/02 12:58	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 17

**5 BB LEAVES #1c EtOAc fraction**

about 25ug on column

Sequence:	25JAN02	Injection Volume:	5.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BA5	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/28/02 13:46	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 18

**7 BB LEAVES #1d ACN fraction**

about 25ug on column

Sequence:	25JAN02	Injection Volume:	5.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BA7	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/28/02 15:22	Sample Amount:	1.0000
Run Time (min):	30.01		



No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	


Figure 19



**8 BB LEAVES #4 ACN**

about 25ug on column

Sequence:	25JAN02	Injection Volume:	5.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BA8	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/28/02 16:10	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 20

**9 BB LEAVES #1E EtOH fraction**

about 25ug on column

Sequence:	25JAN02	Injection Volume:	5.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BA9	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/28/02 16:58	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 21

**10 BB LEAVES #5 EtOH**

about 25ug on column

Sequence:	25JAN02	Injection Volume:	5.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BA10	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/28/02 17:46	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 22

**2 BB STALKS #1Hexane**

about 100ug on column

Sequence:	04Jan02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	GA2	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/4/02 12:38	Sample Amount:	1.0000
Run Time (min):	30.01		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 23

**3 BB STALKS #1b DCM fraction**

about 100ug on column

Sequence:	04Jan02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	GA3	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/4/02 13:12	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 24

**4 BB STALKS #2 DCM**

about 100ug on column

Sequence:	04Jan02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	GA4	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/4/02 13:46	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 25

**5 BB STALKS #1c EtOAc fraction**

about 100ug on column

Sequence:	04Jan02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	GA5	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/4/02 14:20	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 26

**7 BB STALKS #1d ACN fraction**

about 100ug on column

Sequence:	04Jan02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexahe	Channel:	UV_VIS_1
Vial Number:	GA7	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/4/02 15:28	Sample Amount:	1.0000
Run Time (min):	30.00		



No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	


Figure 27



**8 BB STALKS #4 ACN**

about 100ug on column

Sequence:	04Jan02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	GA8	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/4/02 16:02	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 28

**9 BB STALKS #1E EtOH fraction**

about 100ug on column

Sequence:	04Jan02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	GA9	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/4/02 16:36	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 29

**10 BB STALKS #5 EtOH**

about 100ug on column

Sequence:	04Jan02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	GA10	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/4/02 17:10	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 30

**2 BB STEMS #1Hexane**

about 100ug on column

Sequence:	03JAN02	Injection Volume:	7.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BA2	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/3/02 13:35	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 31

**3 BB STEMS #1b DCM fraction**

about 100ug on column

Sequence:	03JAN02	Injection Volume:	35.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BA3	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/3/02 14:09	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 32

**4 BB STEMS #2 DCM**

about 100ug on column

Sequence:	03JAN02	Injection Volume:	7.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BA4	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/3/02 14:43	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 33

**5 BB STEMS #1c EtOAc fraction**

about 100ug on column

Sequence:	03JAN02	Injection Volume:	50.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BA5	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/3/02 15:17	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret. Time min	Peak Name	Height mAU	Area mAU*min	Rel. Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 34

**7 BB STEMS #1d ACN fraction**

about 100ug on column

Sequence:	03JAN02	Injection Volume:	7.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BA7	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/3/02 16:25	Sample Amount:	1.0000
Run Time (min):	30.00		



No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	


Figure 35



**8 BB STEMS #4 ACN**

about 100ug on column

Sequence:	03JAN02	Injection Volume:	5.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BA8	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/3/02 16:59	Sample Amount:	1.0000
Run Time (min):	30.01		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 36

**9 BB STEMS #1E EtOH fraction**

about 100ug on column

Sequence:	03JAN02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BA9	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/3/02 17:33	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 37

**10 BB STEMS #5 EtOH**

about 100ug on column

Sequence:	03JAN02	Injection Volume:	5.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BA10	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/3/02 18:07	Sample Amount:	1.0000
Run Time (min):	30.01		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 38

**12 BB ROOT #1Hexane**

about 80ug on column

Sequence:	03Jan02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BB1	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/3/02 19:15	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 39

**13 BB ROOT #1b DCM fraction****about 80ug on column**

Sequence:	03Jan02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BB2	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/3/02 19:49	Sample Amount:	1.0000
Run Time (min):	30.01		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 40

**14 BB ROOT #2 DCM**

about 80ug on column

Sequence:	03Jan02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BB3	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/3/02 20:23	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 41

**15 BB ROOT #1c EtOAc fraction**

about 80ug on column

Sequence:	03Jan02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BB4	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/3/02 20:57	Sample Amount:	1.0000
Run Time (min):	30.00		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 42

**17 BB ROOT #1d ACN fraction**

about 80ug on column

Sequence:	03Jan02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BB6	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/3/02 22:05	Sample Amount:	1.0000
Run Time (min):	30.00		



No.	Ret. Time min	Peak Name	Height mAU	Area mAU*min	Rel. Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	


Figure 43



**18 BB ROOT #4 ACN**

about 80ug on column

Sequence:	03Jan02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BB7	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/3/02 22:39	Sample Amount:	1.0000
Run Time (min):	30.01		




No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 44

**19 BB ROOT #1E EtOH fraction**

about 80ug on column


Sequence:	03Jan02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BB8	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/3/02 23:13	Sample Amount:	1.0000
Run Time (min):	30.00		



No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	


Figure 45

<b>20 BB ROOT #5 EtOH</b>			
<b>about 80ug on column</b>			
Sequence:	03Jan02	Injection Volume:	10.0
Sample Name:	BB stalks #1a Hexane	Channel:	UV_VIS_1
Vial Number:	BB9	Wavelength:	200
Sample Type:	unknown	Bandwidth:	10
Control Program:	plants	Dilution Factor:	1.0000
Quantif. Method:	general	Sample Weight:	1.0000
Recording Time:	1/3/02 23:47	Sample Amount:	1.0000
Run Time (min):	30.00		



No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount ug	Type
Total:			0.000	0.000	0.00	0.000	

Figure 46



Peak	Retention Time	[M+1] <sup>+</sup>	[M-1] <sup>-</sup>	MW	Structure
1	3.32		239	240	unknown
2	4.32		239	240	unknown
3	5.72		153	154	Protocatechuic acid
4	6.53		153	154	Gentisic acid
5	8.29		341	342	unknown
6	13.32	419		418	Cyanidin-3-arabinoside
7	17.01	493		492	Malvidin-3-galactoside
8	18.13		479	480	Myricetin-3-glucoside
9	20.89	303	301	302	Ellagic acid
10	21.44	479	477	478	Tamarixetin-3-glucoside
11	23.89	319	317	318	Myricetin
12	26.90	303	301	302	Quercetin




Figure 47

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/10200

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : A61K 35/78  
 US CL : 424/732, 773, 774, 775, 777

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/732, 773, 774, 775, 777

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
 Healing Herbs

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
 USPT, PGPB, JPAB, EPAB, DWPI, MEDLINE, EMBASE, BIOSIS, CAPLUS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CASTLEMAN, M. The Healing Herbs: The Ultimate Guide to the Curative Power of Nature's Medicines. (Pennsylvania): Rodale Press. 1991, pages 141 and 142.	1-30
A	PERLMUTTER, F. et al. Effect of Soil Media, Photoperiod, and Nitrogenous Fertilizer on the Growth of Blueberry Seedlings. Proceedings of the American Society for Horticultural Science. 1942, Vol. 40, pages 341-346.	1-30

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance  
 "B" earlier application or patent published on or after the international filing date  
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
 "O" document referring to an oral disclosure, use, exhibition or other means  
 "P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;"

document member of the same patent family

Date of the actual completion of the international search

30 July 2003 (30.07.2003)

Date of mailing of the international search report

15 AUG 2003

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

Susan Coe

Telephone No. (703)308-0196